Back to search

Peptide record

TPDB42904

IDP-LLCb01 Anticancer standard
25 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42904
IDP-LLCb01
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 25-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
RRRRRRRSKAPKVVILSKALEYLQA
Physicochemical Analysis
C133H240N50O32
NDCGHMFTW
R
3051.68
12.53
10
1
10
+9
8.65
-1.000
97.60
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
1490
48.83
4
Residue Composition
number
3
A
7
R
0
N
0
D
0
C
1
E
1
Q
0
G
0
H
1
I
3
L
3
K
0
M
0
F
1
P
2
S
0
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 3 R: 7 N: 0 D: 0 C: 0 E: 1 Q: 1 G: 0 H: 0 I: 1 L: 3 K: 3 M: 0 F: 0 P: 1 S: 2 T: 0 W: 0 Y: 1 V: 2
Chemical Descriptors
25
C133H240N50O32
3051.68
12.53
+9
8.65
-1.000
Free
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

EC50
EC50 ~ 5 µM
Anticancer
5 µM

Target

Lung Cancer
NCl-H187
Lung

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

EC50
EC50 ~ 2.5 µM
Anticancer
2.5 µM

Target

Lung Cancer
NCl-H82
Lung

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1
Evidence 3 Activity

Activity

EC50
EC50 ~ 5 µM
Anticancer
5 µM

Target

Lung Cancer
NCl-H510A
Lung

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1